Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple FDC bioequivalence study in healthy volunteers
NCT07182383Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bempedoic acid + ezetimibe + rosuvastatin in hypercholesterolemia (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Area Under the Curve at 72 hours and Maximum Observed Concentration at 72 hours. Started Sep 2025; status: completed.
02
Drugs
bempedoic acid + ezetimibe + rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07182383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182383.